KYAN Technologies
June 23, 2026
Theater 1
Type: Company Presentation
Focus Area:
Diagnostics and Personalized Medicine
Ever since the first anticancer drugs were discovered combination therapies were in the focus of attention because very few single drugs carry the potential to fundamentally change the trajectory of cancer. However, the rational design of drug combinations remains a challenge which leads to tumor resistance.
KYAN has developed Optim.AI™, a functional precision medicine platform that combines small data AI with biological experiments to analyze the functional response of drug-dose combinations. With limited live cancer cells, Optim.AI™ identifies over 500k drug-dose combinations in each of its test. The clinical validation of Optim.AI™ has been demonstrated >80% clinical response accuracy across 20+ cancer types. Optim.AI™ test results are sent to the ordering physician within ten days of the sample arriving at our lab.
Optim.AI™ has been approved as a commercial, LDT by the Ministry of Health Singapore (MOH), accredited by CAP, CLIA, and certified according to ISO 13486.
Company HQ City:
Singapore
Company HQ State:
N/A
Company HQ Country:
Singapore
Year Founded:
2022
Lead Product in Development:
Optim.AI
CEO
Hugo Saavedra
Development Phase of Lead Product
Multiple Products in Market
When you expect your next catalyst update?
Q4 2026
What is your next catalyst (value inflection) update?
LDT launch in the USA
Primary Speaker
)
)
)
){kind=logo}
){kind=logo}
)
)
){kind=logo}
){kind=logo}